Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population
Open Access
- 20 December 2005
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 118 (5) , 1275-1278
- https://doi.org/10.1002/ijc.21463
Abstract
Overexpression of MDM2 may attenuate the P53 stress response pathway through direct blocking of P53 transcriptional activity and mediating P53 degradation. Two promoter polymorphisms (one is a T to G substitution at the intronic P53‐response promoter, and the other is a 40‐bp insertion/deletion polymorphism in the constitutive promoter) were identified, and recently the T/G substitution (SNP309) has been demonstrated to alter the levels of MDM2 gene products. In this molecular epidemiological study with 717 incident lung cancer cases and 1,083 cancer‐free controls, we genotyped these 2 promoter polymorphisms of MDM2 and evaluated their associations with risk of lung cancer. We found that there were no significant associations between MDM2 SNP309 variant genotypes and lung cancer risk (adjusted OR = 1.20, 95% CI = 0.95–1.53 for TG and adjusted OR = 1.12, 95% CI = 0.85–1.48 for GG, respectively). Similarly, we did not find evidence for any association between risk of lung cancer and MDM2 insertion/deletion polymorphism. The findings suggest that these two MDM2 promoter polymorphisms may not play a major role in lung cancer susceptibility in this Chinese population.Keywords
This publication has 21 references indexed in Scilit:
- Altered Expression of the Cell Cycle Regulatory Molecules pRb, p53 and MDM2 Exert a Synergetic Effect on Tumor Growth and Chromosomal Instability in Non-small Cell Lung Carcinomas (NSCLCs)Molecular Medicine, 2000
- Alterations of the p16-pRb Pathway and the Chromosome Locus 9p21–22 in Non-Small-Cell Lung CarcinomasThe American Journal of Pathology, 1998
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- A MOLECULAR AND IMMUNOHISTOCHEMICAL STUDY OF THE MDM2 PROTEIN ISOFORMS ANDp53 GENE PRODUCT IN BRONCHOGENIC CARCINOMAThe Journal of Pathology, 1996
- Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53Nature, 1995
- Altered Patterns of MDM2 and TP53 Expression in Human Bladder CancerJNCI Journal of the National Cancer Institute, 1994
- Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53Nature, 1993
- Amplification of a gene encoding a p53-associated protein in human sarcomasNature, 1992
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivationCell, 1992